Aquinox Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:AQXP) Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Today's Range N/A50-Day Range$3.68MA: $3.94▼$4.0352-Week Range N/AVolume266,735 shsAverage Volume239,362 shsMarket Capitalization$94.87 millionP/E RatioN/ADividend YieldN/ABeta-7.37 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AQXP Previous Symbol CUSIPN/A CIK1404644 Webhttp://www.aqxpharma.com/ Phone604-629-9223Debt Debt-to-Equity RatioN/A Current Ratio63.17 Quick Ratio63.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net Income$-31,580,000.00 Net MarginsN/A Return on Equity-30.13% Return on Assets-28.08%Miscellaneous Employees8 Outstanding Shares23,540,000Market Cap$94.87 million Next Earnings DateN/A OptionableOptionable Receive AQXP News and Ratings via Email Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions What is Aquinox Pharmaceuticals' stock symbol? Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP." How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) posted its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43. View Aquinox Pharmaceuticals' Earnings History. Has Aquinox Pharmaceuticals been receiving favorable news coverage? Media coverage about AQXP stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aquinox Pharmaceuticals earned a news impact score of 1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Aquinox Pharmaceuticals. Who are some of Aquinox Pharmaceuticals' key competitors? Some companies that are related to Aquinox Pharmaceuticals include Verrica Pharmaceuticals (VRCA), Lexicon Pharmaceuticals (LXRX), DURECT (DRRX), CymaBay Therapeutics (CBAY), Innate Pharma (IPHYF), Merus (MRUS), Magenta Therapeutics (MGTA), Lannett (LCI), Kiniksa Pharmaceuticals (KNSA), OrganiGram (OGI), Arcus Biosciences (RCUS), Clovis Oncology (CLVS), MediciNova (MNOV), Beyondspring (BYSI) and ProQR Therapeutics (PRQR). What other stocks do shareholders of Aquinox Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), XOMA (XOMA), ZIOPHARM Oncology (ZIOP), Sodastream International (SODA), Alnylam Pharmaceuticals (ALNY) and Century Aluminum (CENX). Who are Aquinox Pharmaceuticals' key executives? Aquinox Pharmaceuticals' management team includes the folowing people: Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 54)Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)Ms. Shelley McCloskey, VP of HR & Admin. (Age 59) How big of a company is Aquinox Pharmaceuticals? Aquinox Pharmaceuticals has a market capitalization of $0.00 and generates $25 million in revenue each year. Aquinox Pharmaceuticals employs 8 workers across the globe.View Additional Information About Aquinox Pharmaceuticals. What is Aquinox Pharmaceuticals' official website? The official website for Aquinox Pharmaceuticals is http://www.aqxpharma.com/. How can I contact Aquinox Pharmaceuticals? Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected] MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 275 (Vote Outperform)Underperform Votes: 216 (Vote Underperform)Total Votes: 491MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/19/2019 by MarketBeat.com StaffFeatured Article: What is diluted earnings per share (Diluted EPS)?